Evaluation of the economic burden of Herpes Zoster (HZ) infection
- PMID: 25483704
- PMCID: PMC4514227
- DOI: 10.4161/hv.36160
Evaluation of the economic burden of Herpes Zoster (HZ) infection
Abstract
The main objective of this systematic review was to evaluate the economic burden of Herpes Zoster (HZ) infection. The review was conducted in accordance with the standards of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" guidelines. The following databases were accessed: ISI/Web of Knowledge (WoS), MEDLINE/PubMed, Scopus, ProQuest, the Cochrane Library and EconLit. Specific literature on health economics was also manually inspected. Thirty-three studies were included. The quality of the studies assessed in accordance with the Consolidated Health Economic Evaluation Reporting Standards checklist was good. All studies evaluated direct costs, apart from one which dealt only with indirect costs. Indirect costs were evaluated by 12 studies. The economic burden of HZ has increased over time. HZ management and drug prescriptions generate the highest direct costs. While increasing age, co-morbidities and drug treatment were found to predict higher direct costs, being employed was correlated with higher indirect costs, and thus with the onset age of the disease. Despite some differences among the selected studies, particularly with regard to indirect costs, all concur that HZ is a widespread disease which has a heavy social and economic burden.
Keywords: Herpes zoster; Post-herpetic neuralgia; direct and indirect cost; economic burden; systematic review.
Figures
References
-
- Johnson RW.. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines 2010; 9:Suppl245 - 262; http://dx.doi.org/10.1586/erv.10.30; PMID: 20192714 - DOI - PubMed
-
- Steiner I.. Herpes virus infection of the peripheral nervous system. Handb Clin Neurol 2013; 115:543 - 58; http://dx.doi.org/10.1016/B978-0-444-52902-2.00031-X; PMID: 23931801 - DOI - PubMed
-
- Weinberg A, Levin MJ.. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342:341 - 57; http://dx.doi.org/10.1007/82_2010_31; PMID: 20473790 - DOI - PubMed
-
- Gilden D, Nagel MA, Cohrs RJ, Mahalingam R.. The variegate neurological manifestations of varicella zoster virus infection. Curr Neurol Neurosci Rep 2013; 13:374; http://dx.doi.org/10.1007/s11910-013-0374-z; PMID: 23884722 - DOI - PMC - PubMed
-
- Thomas SL, Hall AJ.. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004; 4:26 - 33; http://dx.doi.org/10.1016/S1473-3099(03)00857-0; PMID: 14720565 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical